Caduet's Japanese price may set precedent for combinations
This article was originally published in Scrip
Executive Summary
Pfizer's combination cardiovascular product Caduet, Novartis's novel antihypertensive Rasilez and other products have been awarded prices in Japan and will be added to the reimbursement tariff on September 4th, clearing the way for launch.